Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Evolving into a phase II company
Press releases
-
Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440
January 31, 2023
-
AlzeCure selects CD and enters next development phase with Alzstatin ACD680 against Alzheimer’s
January 11, 2023
-
The rights issue is registered and the trading in Paid Subscription Shares ceases
January 10, 2023